Recent Activity

Loading...

DAWN

Day One Biopharmaceuticals, Inc. · NASDAQ

Performance

-4.04%

1W

+12.63%

1M

+6.7%

3M

+32.77%

6M

+12.4%

YTD

+25.84%

1Y

Profile

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Investment Analysis Report: DAWN

Overview

In this investment analysis report, we will delve into the financial statements of DAWN, a company in the Health Technology sector specializing in Pharmaceuticals. We will analyze the company's valuation, financial health, earnings and revenue growth, profitability, operating margin, operating cash flow,...

See more ...

Technical Analysis of DAWN 2024-05-03

Overview:

In analyzing the technical indicators for DAWN stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informe...

See more ...

Recent News & Updates